Acalabrutinib With or Without Obinutuzumab Provides Sustained PFS Benefit in Previously Untreated CLL

Acalabrutinib, as monotherapy or in combination with obinutuzumab, continued to improve progression-free survival vs obinutuzumab and chemotherapy in patients with treatment-naive chronic lymphocytic leukemia, regardless of genomic marker status.

Related Keywords

Oregon ,United States ,Acalabrutinib Calquence ,Jeffp Sharman ,Us Oncology Network ,Willamette Valley Cancer Institute ,Obinutuzumab Vs ,Treatment Naive Chronic Lymphocytic Leukemia ,Year Follow Up ,Acalabrutinib ,Obinutuzumab ,Patients With Treatment Naive Chronic Lymphocytic Leukemia ,D ,Elevate Tn Trial ,Nct02475681 ,The Us Oncology Network ,